[go: up one dir, main page]

HN2003000379A - Derivados de anilinopirazol utiles en el tratamiento de la diabetes - Google Patents

Derivados de anilinopirazol utiles en el tratamiento de la diabetes

Info

Publication number
HN2003000379A
HN2003000379A HN2003000379A HN2003000379A HN2003000379A HN 2003000379 A HN2003000379 A HN 2003000379A HN 2003000379 A HN2003000379 A HN 2003000379A HN 2003000379 A HN2003000379 A HN 2003000379A HN 2003000379 A HN2003000379 A HN 2003000379A
Authority
HN
Honduras
Prior art keywords
diabetes
treatment
anilinopirazol
derivatives
useful
Prior art date
Application number
HN2003000379A
Other languages
English (en)
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of HN2003000379A publication Critical patent/HN2003000379A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE ANILINIPIRAZOL, LAS COMPOSICIONES FARMACEUTICAS, Y A LOS METODOS PARA EL TRATAMIENTO DE LA DIABETES Y DESORDENES RELACIONADOS
HN2003000379A 2002-11-27 2003-11-26 Derivados de anilinopirazol utiles en el tratamiento de la diabetes HN2003000379A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42991702P 2002-11-27 2002-11-27
US49821403P 2003-08-27 2003-08-27

Publications (1)

Publication Number Publication Date
HN2003000379A true HN2003000379A (es) 2005-12-20

Family

ID=32474531

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2003000379A HN2003000379A (es) 2002-11-27 2003-11-26 Derivados de anilinopirazol utiles en el tratamiento de la diabetes

Country Status (16)

Country Link
US (2) US7265144B2 (es)
EP (1) EP1567517A1 (es)
JP (1) JP2006510728A (es)
KR (1) KR20050085170A (es)
AR (1) AR042067A1 (es)
AU (2) AU2003295890A1 (es)
BR (1) BR0316723A (es)
CA (1) CA2507186A1 (es)
HN (1) HN2003000379A (es)
MX (1) MXPA05004621A (es)
MY (1) MY141528A (es)
PE (1) PE20040907A1 (es)
PL (1) PL377164A1 (es)
TW (1) TW200418803A (es)
UY (1) UY28098A1 (es)
WO (2) WO2004050650A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1750698A4 (en) * 2004-05-20 2010-06-02 Bayer Pharmaceuticals Corp 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES
EP1860098B1 (en) * 2005-03-16 2012-11-14 Toyama Chemical Co., Ltd. Novel anthranilic acid derivative or salt thereof
WO2007008627A2 (en) * 2005-07-07 2007-01-18 Abbott Laboratories Apoptosis promoters
WO2007027842A1 (en) * 2005-08-31 2007-03-08 Bayer Healthcare Llc Anilinopyrazole derivatives useful for the treatment of diabetes
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
US8022217B2 (en) 2006-07-31 2011-09-20 Cadila Healthcare Limited Compounds suitable as modulators of HDL
AU2007305016B2 (en) 2006-10-02 2011-11-03 Novartis Ag Compounds and compositions as protein kinase inhibitors
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
CA2698928A1 (en) * 2007-09-28 2009-04-09 Absolute Science, Inc. Compounds and methods for treating zinc matrix metalloprotease dependent diseases
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
US20110190285A1 (en) * 2008-09-19 2011-08-04 Absolute Science, Inc. Methods of treating a botulinum toxin related condition in a subject
ES2443947T3 (es) 2008-09-25 2014-02-21 F. Hoffmann-La Roche Ag Derivados de 3-amino-indazol o de 3-amino-4,5,6,7-tetrahidro-indazol
AR075713A1 (es) 2009-03-03 2011-04-20 Du Pont Pirazoles fungicidas
TWI504350B (zh) 2010-09-01 2015-10-21 Du Pont 殺真菌吡唑及其混合物
TWI568721B (zh) 2012-02-01 2017-02-01 杜邦股份有限公司 殺真菌之吡唑混合物
JP6299591B2 (ja) 2012-07-03 2018-03-28 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
CN103074693A (zh) * 2013-01-18 2013-05-01 桐昆集团股份有限公司 带双导丝辊的poy纺丝卷绕装置
WO2015100213A2 (en) 2013-12-23 2015-07-02 Amazentis Sa Process-scale synthesis of urolithins
CN107635967B (zh) * 2015-06-18 2021-03-26 日本曹达株式会社 二芳基唑化合物和有害生物防除剂
KR102420892B1 (ko) * 2017-05-26 2022-07-14 쟝쑤 애텀 바이오사이언스 앤드 파머수티컬 컴퍼니 리미티드 요산 배출을 촉진시키는 urat1 억제제
US11312722B2 (en) * 2019-05-08 2022-04-26 Trustees Of Boston University Hsp90 inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL263568A (es) * 1960-04-14
US3790576A (en) * 1972-03-20 1974-02-05 Parke Davis & Co 9 substituted 4,9-dihydro-1,3,4,4-tetraalkyl-1h-pyrazolo(3,4-b)quinolines
HUT69739A (en) 1992-03-26 1995-09-28 Dowelanco Process for producing n-heterocyclic nitroanilines and fungicides containing the compounds
DE69532817T2 (de) 1994-11-10 2005-01-13 Millenium Pharmaceuticals, Inc., Cambridge Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
DE19532066A1 (de) 1995-08-31 1997-03-06 Bayer Ag Substituierte 5-Aminopyrazole
FR2763334A1 (fr) 1997-05-13 1998-11-20 Lipha Derives anthraniliques
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US5942520A (en) 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
WO2004076414A2 (en) * 2003-02-27 2004-09-10 Smithkline Beecham Corporation Novel compounds

Also Published As

Publication number Publication date
EP1567517A1 (en) 2005-08-31
US7265144B2 (en) 2007-09-04
MY141528A (en) 2010-05-14
UY28098A1 (es) 2004-06-30
AU2003297565A1 (en) 2004-06-23
TW200418803A (en) 2004-10-01
JP2006510728A (ja) 2006-03-30
BR0316723A (pt) 2005-10-18
WO2004050650A1 (en) 2004-06-17
AR042067A1 (es) 2005-06-08
MXPA05004621A (es) 2005-06-08
CA2507186A1 (en) 2004-06-17
WO2004050651A1 (en) 2004-06-17
HK1087103A1 (zh) 2006-10-06
PL377164A1 (pl) 2006-01-23
PE20040907A1 (es) 2005-01-27
AU2003295890A1 (en) 2004-06-23
US20080064734A1 (en) 2008-03-13
KR20050085170A (ko) 2005-08-29
US20040157904A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
HN2003000379A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes
UY28376A1 (es) Agentes terapéuticos
CR9954A (es) Derivados de pirazina
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
UY28144A1 (es) Agentes terapéuticos
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
CR8649A (es) Derivados de formamidina para el tratamiento de enfermedades
PA8544901A1 (es) Derivados de oxazol
CR8858A (es) Derivados de sulfamato y sulfamida para el tratamiento de epilepsia y trastornos relacionados
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
CL2003002769A1 (es) Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
PA8604201A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975
PA8622401A1 (es) Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico,procesos para su preparacion y su uso como medicamentos
HN2008001666A (es) Derivados acidos de cicloalquilamino
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY28377A1 (es) Agentes terapeuticos
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
UY28839A1 (es) Agentes terapeuticos